Evidence map›Paper›PMID 28814883›Full record

ArticleOncoTargets and therapy2017

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma.

Weifeng Liu, Jie Hu, Kaiqian Zhou, Feiyu Chen, Zheng Wang, Boyi Liao, Zhi Dai, Ya Cao, Jia Fan, Jian Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.

  1. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Exosomal Long Noncoding RNAs Serve as Biomarkers for Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Review
  17. Review
  18. Review
  19. Liquid Biopsy in Hepatocellular Carcinoma.Methods in molecular biology (Clifton, N.J.) · 2023
    Review
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Weifeng LiuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jie HuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Kaiqian ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Feiyu ChenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Boyi LiaoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhi DaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Ya CaoCancer Research Institute, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China.
Jia FanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jian ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhongshan Hospital · CNFudan University · CNCancer Research Institute · USSecond Affiliated Hospital of Zhejiang University · CNShanghai Institute of Organic Chemistry · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive biomarker for many tumors. This study aimed to investigate the potential of circulating miR-125b as a prognostic marker of HCC. Exosomes were extracted from serum samples collected from two independent cohorts: cohort 1: HCC (n=30), chronic hepatitis B (CHB, n=30), liver cirrhosis (LC, n=30); cohort 2: HCC (n=128). We found that miR-125b levels were remarkably increased in exosomes compared to those in serum from patients with CHB, LC, and HCC (

Indexed as

exosomehepatocellular carcinomamiR-125bprognosisserum

Identifiers

PMID28814883
PMCPMC5546809
OpenAlexW2740751697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.